Purpose: Sleep apnoea syndrome (SAS) is often associated with glaucoma, and intermittent hypoxia, present in SAS, can contribute to glaucoma pathogenesis. However, the relationships between SAS, high systemic oxidative stress and the speed of glaucoma progression are unclear. Thus, we investigated these relationships in glaucoma patients with and without SAS. Methods: Peripheral blood samples were collected from 166 eyes of 166 Japanese patients: 42 controls, 109 open-angle glaucoma (OAG) patients without SAS and 15 OAG patients with SAS. Prognostic factors for visual field defect progression were determined with logistic regression. Diacron reactive oxygen metabolites (dROM) and biological antioxidant potential (BAP) were measured with a free radical analyser. Clinical parameters were also recorded. Intergroup comparisons used the Mann-Whitney U test. Results: Multiple regression analysis showed that SAS was a statistically significant contributing factor to fast visual field defect progression, defined as mean deviation (MD) slope ≤À2.0 dB/Y (SAS: odds ratio (OR) = 14.48; p = 0.002). The non-SAS and SAS groups had similar age, sex, intraocular pressure (IOP), axial length and antiglaucoma drug use. The SAS group had a significantly higher dROM level (p = 0.001), BAP level (p = 0.038) and steeper MD slope (p = 0.001) than the non-SAS group. Conclusion: Glaucoma patients with SAS have higher dROM, as well as steeper MD slope, than patients without SAS, suggesting that SAS may induce systemic oxidative stress and promote glaucomatous visual field defect progression.
Introduction
Glaucoma is characterized by the progressive loss of retinal ganglion cells (RGCs). Intraocular pressure (IOP) is known to be the most important risk factor for glaucoma, but many patients with glaucoma have a normal or relatively low IOP range. Consequently, researchers have looked for other contributing factors to explain glaucoma pathogenesis, such as genetics (Guo et al. 2012) , vascular dysregulation ) and oxidative stress (Himori et al. 2016 ). Oxidative stress is also associated with sleep apnoea syndrome (SAS), a disease characterized by intermittent hypoxia that seems to promote the production of reactive oxygen species (ROS), thereby resulting in increased systemic oxidative stress (Prabhakar 2002; Yamauchi et al. 2005) .
In SAS, cyclical episodes of arterial oxygen saturation and desaturation and sleep fragmentation are caused by apnoea and hypopnoea during sleep (Bendel et al. 2008) . Recent data suggest that SAS may be associated with a number of cardiovascular and cerebrovascular events, such as hypertension (Peppard et al. 2000) , cardiac arrhythmia (Monahan et al. 2009 ), ischaemic heart disease (Gottlieb et al. 2010 ) and ischaemic stroke (Yaggi et al. 2005) . Previous studies have demonstrated that SAS is associated with several eye disorders, such as floppy eyelid syndrome (Robert et al. 1997) , keratoconus (Naderan et al. 2015) , papilledema (Purvin et al. 2000) and optic neuropathy (Mojon et al. 1998) . Furthermore, an association between glaucoma and SAS has been reported, with the prevalence of SAS being about 20% in patients with primary open-angle glaucoma (POAG) (Mojon et al. 2000) and normal-tension glaucoma (NTG) (Mojon et al. 2002) . Subsequently, Lin et al. (2013) recently conducted the important recent report on the link between SAS and glaucoma. They determined the 5-year hazard ratio for the development of open-angle glaucoma (OAG) in 1012 subjects who were diagnosed with SAS and performed a comparison with 6072 controls. After adjusting for multiple confounding factors, they found that within the first 5 years of diagnosis, patients with SAS had a hazard ratio for developing glaucoma 1.67 times higher than the controls. The study concluded that SAS was independently associated with an increased risk of POAG and proposed a causative link between SAS and glaucoma. However, the association between markers of systemic oxidative stress and visual field defect progression in glaucoma patients with and without SAS still remains unclear.
In this study, we evaluated markers of systemic oxidative stress and antioxidant capacity in glaucoma patients with and without SAS and control subjects, to determine factors influencing oxidant/antioxidant status. Thus, the purpose of this study was to evaluate the relationship between oxidative stress and conventional clinical findings in eyes with glaucoma and test our hypothesis that SAS induces higher oxidative stress, thereby promoting glaucoma progression.
Patients and Methods
This was a prospective study of 124 consecutive Japanese patients with previously diagnosed bilateral OAG (the eye with worse mean deviation (MD) was chosen for the analysis), including 92 patients with NTG and 32 patients with POAG. The subjects were enrolled at the glaucoma subspecialty clinic of Tohoku University Hospital between April 2013 and March 2016.
A detailed medical history was obtained from all patients, and they were questioned for symptoms and signs suggesting respiratory sleep disorders. If they had any symptoms suggesting SAS, such as loud snoring, observed apnoea or excessive daytime sleepiness, they were referred to the Sleep Laboratory at the Department of Respiratory Medicine, Tohoku University Hospital, to confirm the presence of sleep apnoea with full-night comprehensive polysomnography. The results of this analysis included the apnoea-hypopnoea index (AHI), defined as the number of obstructive and central apnoeas and hypopnoeas per hour of sleep (calculated by dividing the total number of events by the total sleep time). Mild SAS was defined as an AHI greater than 5 and 15, moderate SAS as AHI >15 and <30 and severe SAS as an AHI >30. All patients with glaucoma in this study had moderate or severe SAS. The study included 109 eyes of 109 OAG patients without SAS and 15 eyes of 15 OAG patients with SAS. The non-SAS group, with no symptoms suggesting SAS, included 83 patients with NTG and 26 patients with POAG, and the SAS group included nine patients with NTG and six patients with POAG, none of whom were undergoing continuous positive airway pressure (CPAP) treatment at the time of the study.
All subjects underwent a complete ophthalmic examination, including measurement of best-corrected visual acuity (BCVA), represented as logarithm of the minimal angle of resolution (logMAR) units and axial length, as well as slit lamp biomicroscopy, gonioscopy, funduscopy and evaluation of the optic disc with a 90-dioptre lens. All evaluations were performed by glaucoma specialists. Additionally, Goldmann applanation tonometry was used to IOP in all OAG eyes under antiglaucoma therapy.
Subjects were excluded if they had other ophthalmic conditions, such as any other type of secondary glaucoma, high myopia (below À8D), hyperopia (above +3D) or high IOP (≥21 mmHg) under glaucoma medication. Subjects were also excluded if they had severe systemic diseases, such as cancer, autoimmune disease or kidney failure. The presence or absence of diabetes, hyperlipidaemia and a current smoking habit was recorded before the samples were collected. Forty-two control subjects were recruited from patients who visited Tohoku University Hospital for treatment of either cataracts or epiretinal membrane (ERM), but not glaucoma. This study followed the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the Tohoku University School of Medicine (study 2016-1-708). Written informed consent was obtained from all subjects at the time of sample collection.
Visual field test
Mean deviation (MD) values were obtained with the Swedish interactive threshold algorithm standard strategy of the 24-2 program of the Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA, USA). The eyes with worse MD were included in the statistical analysis. Reliable visual field tests were defined as those with a false negative rate <15%, a false-positive rate <15% and fixation loss <20%. Progression was determined according to MD slope, which was calculated from five or more reliable sets of data with Hfa Files software (Beeline Co. Ltd., Tokyo, Japan). The patients were defined as having slow, moderate or fast visual field defect progression if they had an MD slope worse than À0.5 dB/Y, À1.0 dB/Y or À2.0 dB/Y, respectively.
Blood sampling and analysis
Assays of oxidative stress in plasma and blood serum were performed with the dROM test, which measures the total oxidant capacity of samples (mainly in the form of hydroperoxide) relative to the chromogenic substrate N, N-diethylparaphenylendiamin. Total plasma antioxidant capacity was assayed using the biological antioxidant potential (BAP) test, which measures the capacity of a sample to reduce ferric ions to ferrous ions with a thiocyanate derivative as a chromogen. This method is the same as that used in previously published reports and is routinely used to measure oxidative stress levels (Tanito et al. 2012 (Tanito et al. , 2015 .
Blood samples were collected at least 3 hr after the last meal. All blood analyses were performed with a free radical analyser system (Free Carpe Diem, Wismerll Company Ltd., Tokyo, Japan). This system has a spectrophotometric device reader, a thermostatically regulated minicentrifuge and a measurement kit. All analyses were performed within 1 hr to prevent the influence of falsely high or low metabolites on the results. The analyses were performed according to the manufacturer's instructions. Briefly, blood samples were collected in a tube and immediately processed by centrifuge (6000 rpm for 2 min). For the dROM test, 20 ll of sample and an acidic buffer were mixed, and a chromogenic substrate was then added. After automated incubation in the analyser, the absorbance of the sample at a wavelength of 546 nm was recorded. The results were expressed in conventional units called U. Carr (Carrelli units). One U. Carr unit corresponds to 0.8 mg/l of hydrogen peroxide. For the BAP test, 20 ll of sample was mixed into a coloured solution (at 505 nm) containing ferric chloride (FeCl3; a source of ferric ions, Fe 3+ ). Antioxidants in the sample caused the Fe 3+ to be reduced to Fe 2+ (ferrous ions), leaving oxidized blood plasma barrier molecules and a decoloured solution. After incubation for 5 min at 37°C, the decoloration in the sample at 505 nm was quantifiable, and the results were expressed in lmol/l of reduced Fe 3+ .
Statistical analysis
The Mann-Whitney U test and Fisher's exact test were used to determine the significance of differences between groups. Prognostic factors for visual field defect progression were determined by logistic regression analysis. All results are expressed as the mean AE SD. For all tests, p values < 0.05 were considered to be statistically significant. Statistical analysis was performed with the JMP Pro 11 software (SAS Institute Japan, Inc., Tokyo, Japan).
Results
One hundred and twenty-four Japanese patients with glaucoma (50 male, 74 female) and 42 normal subjects (13 male, 29 female) were recruited into this study. The clinical characteristics of the control and patients with OAG are shown in Table 1 . Visual acuity (VA) was significantly higher in the control group than the overall group of patients with OAG (p = 0.002). There were no significant differences between any groups in the ratio of subjects with hyperlipidaemia, diabetes or a current smoking habit.
To confirm the association of SAS with fast visual field progression (i.e. MD slope ≤À2.0 dB/Y), as well as with other parameters, we performed a multiple logistic regression analysis (Table 2 ). This showed that only one factor was statistically associated with fast visual field defect progression: SAS (odds ratio (OR) = 14.48; p = 0.002).
The clinical characteristics of the OAG patients with and without SAS are shown in Table 3 . The OAG patients with SAS had significantly higher dROM and BAP than the OAG patients without SAS (p = 0.001 and p = 0.038). A comparison of the number of antiglaucoma drugs being taken by each patient (recorded at the time oxidative stress was measured) showed no significant differences between any groups (p = 0.212). We used MD slope to compare the progression of visual field loss in OAG patients with and without SAS and found that the OAG patients with SAS had faster progression and higher dROM and BAP than those without SAS (MD slope À1.62 AE Table 3 and Fig. 1 ). We also used MD slope to examine the relationship between speed of progression and the presence of SAS. We found that groups of patients with low, moderate or high MD slope (À0.5 dB/Y, from À0.5 to À2.0 dB/Y and less than À2.0 dB/Y, respectively) had a significantly different incidence of SAS (p < 0.001) ( Table 4) .
Discussion
This study builds upon recent findings that patients with SAS have a high incidence of glaucoma (Lin et al. It has long been known that patients with SAS have a high incidence of glaucoma (Mojon et al. 1999) . Lin et al. (2011) reported that the prevalence of glaucoma was especially high in patients with moderate or severe SAS. Additionally, Karakucuk et al. (2008) reported that IOP was positively correlated with the severity of SAS, a finding that was considered compatible with existing knowledge that high IOP often underlies glaucoma. Nevertheless, some SAS patients with glaucoma continue to progress even when IOP is controlled. Furthermore, recent findings have complicated our view of IOP changes in SAS. Contact lens sensorbased continuous IOP monitoring has shown that IOP levels decline significantly during apnoea events (Shinmei et al. 2016) . Thus, although it is clear that SAS and glaucoma are related, the role of IOP changes in this relationship is unknown. Glaucoma is a complex, multifactorial disease, in which a variety of pathomechanisms is believed to contribute to the loss of the RGCs (Nakazawa 2016) . Thus, many IOPindependent factors may link SAS and glaucoma, including optic nerve head blood flow (Shiga et al. 2013 , inflammation (Minhas et al. 2016 ) and oxidative stress (Himori et al. 2016) .
Previous studies have linked SAS with oxidative stress and endothelial dysfunction and have shown the effectiveness of CPAP in ameliorating these effects. Intermittent hypoxia in SAS can increase oxidative stress and ROS levels, activating various pathways of systemic inflammation, thereby inducing endothelial dysfunction. Animal models of intermittent hypoxia have shown that it can cause the oxidation of various macromolecules, such as proteins, nucleic acids and lipids (Xu et al. 2004) . In healthy human subjects, a study showed that intermittent hypoxia (induced artificially for six hours a day for 4 days) led to increased DNA oxidation and increased sensitivity to hypoxia (Pialoux et al. 2009 ). Various case-control studies have also supported an association between SAS and endothelial dysfunction. Generally, oxidative stress is thought to be a major contributor to endothelial damage and senescence, as it can decrease nitric oxide (NO) production, which promotes inflammation and disturbs normal endothelial cell functions (Berry et al. 2001; Minuz et al. 2006) . In patients with SAS, specifically, expression of an oxidative stress marker, nitrotyrosine, is elevated in the endothelial cells (Jelic et al. 2008) .
Imbalance between NO (a vasodilator) and endothelin (a vasoconstrictor) causes the blood supply to become insufficient for the nourishment of the retinal nerve fibre layer and optic nerve head. Microvascular changes in the retina and optic disc are therefore of particular interest when considering the link between SAS and optic nerve pathology. Additional increases in IOP have been noted in patients with SAS and glaucoma that receive CPAP therapy (Kiekens et al. 2008) . Thus, if glaucomatous changes develop during therapy, patients are sometimes prescribed topical IOP-lowering therapy. Cessation of CPAP is generally not considered, because CPAP is known to decrease the risk of vascular perfusion damage in patients with SAS and to have a beneficial effect. Promisingly, Jurado-Gamez et al. (2011) reported CPAP treatment significantly reduced levels of 8-hydroxy-2 0 -deoxyguanosine (8-OHdG), an oxidative stress marker, in a group of patients with SAS. Furthermore, Jelic et al. (2008) reported that 4 weeks of CPAP treatment improved endothelial cell function and decreased oxidative stress in patients with SAS when CPAP was used for at least four hours a night. These findings indicate that CPAP treatment is highly effective in patients with SAS and can reduce chronic sleep deprivation after SAS treatment, reduce oxidative stress and ameliorate endothelial dysfunction, suggesting that SAS treatment may also have an effect on the progression of SASrelated glaucoma.
The key new finding of this study was that patients with SAS and glaucoma are characterized by faster glaucoma progression. We hope that this information will encourage clinicians to check for the presence of SAS in patients with glaucoma that progresses rapidly despite good control of IOP, in order to provide appropriate treatments, such as CPAP. We speculate that this faster glaucoma progression is related to the same factors that have been previously reported to influence the presence of glaucoma in patients with SAS, that is, hypoxia and increased oxidative stress. We previously found that 8-OHdG levels were correlated with optic nerve head blood flow in patients with glaucoma (Himori et al. 2016) , likely due to endothelial dysfunction. Many reports have linked reduced ocular blood flow and the speed of glaucoma progression (Ernest et al. 2013; Nakazawa 2016) . Moreover, hypoxia in glaucoma patients with SAS has been shown to decrease PaO 2 and increase PaCO 2, affecting optic nerve perfusion and oxygenation and leading to optic neuropathy (Lin et al. 2011) . Endothelial cell dysfunction has been implicated in these effects. Thus, current and previous findings suggest that hypoxia, elevated oxidative stress, endothelial dysfunction and decreased ocular blood flow may accelerate glaucoma progression in patients with SAS. Clinical interventional trials may therefore be needed to determine the effectiveness of SAS treatments for SAS-related glaucoma and to better understand the causal relationship between SAS and glaucoma.
Our study was affected by several limitations. First, the patients with OAG were classified as non-SAS based only on the absence of SAS symptoms and did not undergo overnight polysomnography examinations. Therefore, patients with SAS may have inadvertently been included in the non-SAS group, affecting the strength of our comparison. Despite this, the dROM levels were significantly different in these groups, suggesting that this should not have affected our conclusions. Second, all the patients with OAG in this study were currently undergoing treatment with topical antiglaucoma medication. This may have affected our ability to accurately determine the influence of SAS on OAG in these patients. Nevertheless, we did not find a significant difference in the number of medications in the OAG patients with SAS and without SAS. Third, the OAG patients with SAS had a normal average body mass index (BMI) in this study. Typically, middle-aged or older men with obesity and with a long history of loud snoring are most affected by SAS (Douglass et al. 1994) . However, while the normal BMI of our subjects would be surprising in a population of European patients with SAS, it is typical in Japan (Li et al. 1999) . In addition to obesity, anatomical features such as a short jaw are significant contributors to SAS in Japanese subjects. In this study, all 15 patients with SAS were diagnosed with the obstructive type, so we are unable to discuss possible differences based on SAS type. Therefore, we consider that our results lend sufficient support to our conclusions.
The most important finding of this study was that the speed of visual field deterioration was higher in OAG patients with SAS than in patients without SAS. This finding should shed new light on the relationship between SAS and rapid progression of glaucoma, and we hope that it will lead to new therapeutic strategies and improve understanding of the connected risks of glaucoma and SAS. However, this study included only a small sample size, calling for additional, larger-scale research. Moreover, evidence for the association between oxidative stress and glaucoma progression remains inconclusive, but we anticipate that further research will reveal causal relationships between SAS, systemic oxidative damage and glaucoma. Further study should clarify our findings and allow the exploration of the mechanisms underlying these relationships. 
